Xifaxan (Rifaximin) Indications and Dosing
Xifaxan (rifaximin) has three FDA-approved indications with specific dosing regimens: 200 mg three times daily for 3 days for travelers' diarrhea, 550 mg twice daily for hepatic encephalopathy prevention, and 550 mg three times daily for 14 days for IBS-D (with retreatment as needed). 1
FDA-Approved Indications and Dosing
1. Travelers' Diarrhea
- Dose: 200 mg orally three times daily for 3 days 1
- Population: Adults and children ≥12 years
- Target pathogen: Non-invasive Escherichia coli strains
- Can be taken with or without food 1
Important caveat: Rifaximin should NOT be used if fever or bloody diarrhea is present, as these patients (particularly those with Campylobacter jejuni) had clinical cure rates of only 23% in clinical trials 1. These dysentery-like syndromes require alternative antibiotics.
2. Hepatic Encephalopathy (HE) - Secondary Prophylaxis
- Dose: 550 mg orally twice daily, ongoing 1
- Population: Adults ≥18 years with advanced liver disease
- Indication: Reduction in risk of overt HE recurrence
- Can be taken with or without food 1
Key clinical context from guidelines: According to the 2022 EASL guidelines, rifaximin as adjunct to lactulose is recommended as secondary prophylaxis following >1 additional episodes of overt HE within 6 months of the first episode (strong recommendation, moderate quality evidence) 2. The 2018 IDSA/SHEA guidelines specify that for second or subsequent recurrence of C. difficile infection, vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days is one treatment option 3, though this is a weak recommendation with low quality evidence.
Long-term safety data: Rifaximin 550 mg twice daily has been studied for up to 24 months with median exposure of 427 days, showing no increase in adverse events, C. difficile infections, or bacterial resistance development 4. The HE-related hospitalization rate remained low (0.21 per person-year) compared to placebo (0.72) 4.
3. Irritable Bowel Syndrome with Diarrhea (IBS-D)
- Dose: 550 mg orally three times daily for 14 days 5
- Population: Adults ≥18 years
- Retreatment: Can repeat up to 2 additional 14-day courses if symptoms recur 5
Clinical efficacy from guidelines: The 2022 AGA guidelines provide a conditional recommendation for rifaximin in IBS-D based on moderate quality evidence 5. In phase 3 trials, rifaximin showed:
- FDA responder rate (simultaneous improvement in abdominal pain and stool consistency): RR 0.85 (95% CI 0.78-0.94) 5
- Bloating relief: RR 0.86 (95% CI 0.70-0.93) 5
- Abdominal pain relief: RR 0.87 (95% CI 0.80-0.95) 5
Retreatment strategy: For patients who initially respond but develop recurrent symptoms, the same 14-day course can be repeated. In the retreatment trial, patients who relapsed after initial response were re-treated with rifaximin 550 mg three times daily for 14 days, with assessment during the 4 weeks following each treatment course 5.
Off-Label/Emerging Uses (Not FDA-Approved)
Clostridium difficile Infection - Recurrent Cases
Per 2018 IDSA/SHEA guidelines: For second or subsequent recurrence of CDI, one option is vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days 3. This is a weak recommendation with low quality evidence.
Pediatric dosing note: Rifaximin is not FDA-approved for children <12 years of age, and there is no established pediatric dosing for CDI 3.
Small Intestinal Bacterial Overgrowth (SIBO)
While not FDA-approved, research suggests rifaximin 1600 mg/day (divided doses) for 7 days shows higher decontamination rates (80%) compared to 1200 mg/day (58%) for SIBO treatment 6. However, this remains investigational.
Mechanism and Clinical Pearls
Rifaximin is a non-absorbable rifamycin derivative that inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase 1. Its minimal systemic absorption (<0.4%) results in high intestinal concentrations with low systemic adverse effects 7, 8.
Beyond antimicrobial effects: Rifaximin modulates gut microbiota, strengthens the epithelial barrier, and exerts pregnane X receptor (PXR)-mediated anti-inflammatory effects 9. These pleiotropic properties explain efficacy across multiple gastrointestinal conditions.
Common pitfalls to avoid:
- Do not use for invasive diarrhea (fever, bloody stools) - efficacy is poor 1
- For HE prevention, rifaximin is used as adjunct to lactulose, not monotherapy in most cases 2
- For IBS-D, improvements may be modest (9% absolute benefit over placebo) and may not be clinically meaningful for all patients 5
- Cost considerations are significant, particularly for long-term HE prophylaxis 9